Publications by authors named "Masao Harada"

Claim this Profile
E
Efficacy and feasibility of percutaneous needle biopsy in molecular profiling of thoracic cancers via next-generation sequencing.
Yuma Sato, Hiroshi Yokouchi, Keita Tagami, Hiroyuki Nagashima, Noriyuki Yamada, Masao Harada

Respir Investig· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804).
Atsushi Nakamura, Masao Harada, Kana Watanabe, Toshiyuki Harada, Akira Inoue

Med Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of OX40 lymphocytes in tumor stroma of surgically resected small-cell lung cancer.
Hiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, Toraji Amano, Takayuki Ohkuri, Masao Harada

Oncoimmunology· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004).
Hironori Takagi, Songji Zhao, Satoshi Muto, Hiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, Masao Harada

Lung Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).
Shin-Ichi Fukumoto, Satoshi Oizumi, Masao Harada, Noriaki Sukoh, Kosuke Nakano, Toshiyuki Harada

Cancer Chemother Pharmacol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of somatic mutation in surgically resected small-cell lung cancer by targeted exome sequencing: association with longer relapse-free survival.
Hiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, Shigeo Yamazaki, Hajime Kikuchi, Masao Harada

Heliyon· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Hajime Asahina, Satoshi Oizumi, Kei Takamura, Toshiyuki Harada, Masao Harada

Lung Cancer· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Megumi Furuta, Jun Sakakibara-Konishi, Hajime Kikuchi, Hiroshi Yokouchi, Hiroshi Nishihara, Masao Harada, Toshiyuki Harada

Oncologist· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective analysis of the association between skeletal-related events and quality of life in patients with advanced lung cancer (CSP-HOR13).
Hiroshi Kunikane, Isao Yokota, Nobuyuki Katakami, Koji Takeda, Koichi Takayama, Masao Harada

Oncol Lett· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Taichi Takashina, Hajime Asahina, Satoshi Oizumi, Noriyuki Yamada, Masao Harada, Toshiyuki Harada

Int J Clin Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoradiotherapy in Elderly Patients With Non-Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301).
Shinji Atagi, Junki Mizusawa, Satoshi Ishikura, Toshiaki Takahashi, Hiroaki Okamoto, Masao Harada

Clin Lung Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
Masahiro Watanabe, Satoshi Oizumi, Shizuka Kiuchi, Noriyuki Yamada, Hiroshi Yokouchi, Masao Harada

Intern Med· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Naoto Morikawa, Akira Inoue, Shunichi Sugawara, Makoto Maemondo, Toshiyuki Harada, Masao Harada

Lung Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker.
Hiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, Takashi Ishida, Shigeo Yamazaki, Masao Harada

Oncotarget· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
Tomohide Tamura, Katsuyuki Kiura, Takashi Seto, Kazuhiko Nakagawa, Makoto Maemondo, Masao Harada

J Clin Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of Notch1 and Numb in small cell lung cancer.
Hajime Kikuchi, Jun Sakakibara-Konishi, Megumi Furuta, Hiroshi Yokouchi, Hiroshi Nishihara, Masao Harada, Toshiyuki Harada

Oncotarget· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer.
Tomoka Kitao, Kenji Hirata, Katsumi Shima, Takashi Hayashi, Mitsunori Sekizawa, Masao Harada

BMC Cancer· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A).
Hiroshi Yokouchi, Takashi Ishida, Shigeo Yamazaki, Hajime Kikuchi, Satoshi Oizumi, Masao Harada, Toshiyuki Harada

Lung Cancer· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Akira Inoue, Shunichi Sugawara, Makoto Maemondo, Yoshiaki Mori, Satoshi Oizumi, Masao Harada

Lung Cancer· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
Tatsuro Fukuhara, Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Masao Harada

Lung Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies.
Naoto Morikawa, Yuji Minegishi, Akira Inoue, Makoto Maemondo, Kunihiko Kobayashi, Masao Harada

Expert Opin Pharmacother· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207†.
Hiroko Tsukada, Akira Yokoyama, Koichi Goto, Tetsu Shinkai, Masao Harada

Jpn J Clin Oncol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.
Kenya Kanazawa, Hiroshi Yokouchi, Xintao Wang, Takashi Ishida, Yuka Fujita, Toshiyuki Harada, Masao Harada

Cancer Chemother Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803.
Akira Inoue, Shunichi Sugawara, Masao Harada, Kunihiko Kobayashi, Toshiyuki Kozuki

J Thorac Oncol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Yoshifumi Matsumoto, Makoto Maemondo, Yoshiki Ishii, Koichi Okudera, Yoshiki Demura, Masao Harada

Lung Cancer· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis